Pfizer Faces New International Patent Lawsuits Over COVID-19 Vaccine

Regulation
โดย Simply Wall St·Read original
Summary · why it matters

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines, extending the legal dispute beyond the existing U.S. litigation into Canada and several European countries under the Unified Patent Court. The lawsuits seek monetary damages and permanent injunctions that could, in a worst-case scenario, affect Pfizer's ability to sell the vaccines in some markets. The dispute centers on lipid nanoparticle technology used in mRNA delivery, adding legal and operational risks to Pfizer's key vaccine franchise. Pfizer's stock last closed at $25.05, with a 10.5% gain over the past year but declines of 19.5% over three years and 22.6% over five years. The legal process is typically lengthy, giving Pfizer time to pursue defenses or settlements, but investors now face another potential source of cash outflows and operational constraints.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 3 stocks
Pfizer Inc
PFE
▼ NegativeRegulationrelevance

Pfizer faces new patent lawsuits in Canada and Europe over its COVID-19 vaccine, risking injunctions and cash outflows.

Arbutus Biopharma Corp
ABUS
▲ PositiveCompetitionrelevance

Arbutus and Genevant filed patent lawsuits against Pfizer/BioNTech, potentially strengthening their IP position and licensing prospects.

BioNTech SE
22UA
▼ NegativeRegulationrelevance

BioNTech, as co-defendant with Pfizer, faces patent lawsuits that could affect its vaccine franchise.

Off-coverage companies 1

Genevant SciencesPrivate▲ Positive
Competitionrelevance

Genevant, co-plaintiff with Arbutus, filed lawsuits that could strengthen its patent position and lead to licensing revenue.

© 2026 MarketDXNews